We are live on ! Find out more
EDSA icon

Edesa Biotech

12 hedge funds and large institutions have $910K invested in Edesa Biotech in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more capital inflows, than outflows

Capital inflows: $655K | Capital outflows: $298K

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

9% more funds holding

Funds holding: 11 → 12 (+1)

0.46% more ownership

Funds ownership: 1.58% → 2.04% (+0.46%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

EDSA Hedge Fund Activity: Q4 2020 in Review

12 of the 5,680 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q4 2020, worth a combined $910K — down 26% from $1.22M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new EDSA positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $433K. The largest seller was FNY Investment Advisers, cutting an estimated $265K.

  • 12 institutional investors held Edesa Biotech (EDSA) as of Q4 2020, up from 11 in Q3 2020.
  • Funds reported $910K of Edesa Biotech stock for Q4 2020, down 26% quarter-over-quarter.
  • 2 funds opened new Edesa Biotech positions in Q4 2020 and 1 closed out, a net change of +1 holder.
  • The largest Edesa Biotech buyer in Q4 2020 was Renaissance Technologies, an estimated $433K added.
  • The largest Edesa Biotech seller in Q4 2020 was FNY Investment Advisers, an estimated $265K sold.

Based on aggregated 13F filings for Q4 2020.